Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial With Controlled Human Malaria Infection to Evaluate the Safety, Immunogenicity, and Protective Efficacy of Two-Antigen and Three-Antigen Plasmodium Falciparum DNA Prime-Adenovirus Boost Malaria Vaccine Regimens in Healthy Malaria Naïve Adults

NCT03341754 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT03341754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03341754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial With Controlled Human Malaria Infection to Evaluate the Safety, Immunogenicity, and Protective Efficacy of Two-Antigen and Three-Antigen Plasmodium Falciparum DNA Prime-Adenovirus Boost Malaria Vaccine Regimens in Healthy Malaria Naïve Adults
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 1
Overall status
Completed
Start date
September 15, 2018
Completion date
March 23, 2020
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malaria